People: Lorus Therapeutics Inc (LRUSF.PK)

LRUSF.PK on OTC Markets Group

0.23USD
17 May 2013
Price Change (% chg)

$-0.00 (-0.83%)
Prev Close
$0.23
Open
$0.23
Day's High
$0.23
Day's Low
$0.23
Volume
300
Avg. Vol
483
52-wk High
$0.58
52-wk Low
$0.19

Search Stocks

Summary

Name Age Since Current Position

Jim Wright

 2011 Chairman of the Board

Aiping Young

 2006 President, Chief Executive Officer, Director

Elizabeth Williams

 2005 Acting Chief Financial Officer, Director - Finance

Yoon Lee

 2008 Vice President - Research

Herbert Abramson

 70 2007 Independent Director

Denis Burger

 69 2011 Independent Director

Mark Vincent

 2007 Independent Director

Warren Whitehead

 2011 Independent Director

Christine Stewart

 IR Officer
» Insider Trading

Biographies

Name Description

Jim Wright

 Dr. Jim A. Wright, Ph.D., is Chairman of the Board of Lorus Therapeutics Inc. Dr. Wright is presently Chief Executive Officer of NuQuest Bio Inc. since 2006 and until 2005 was Professor in the Faculties of Science and Medicine at the University of Manitoba. As of July 1, 2010, Dr. Wright accepted a position as an Adjunct Professor in the Department of Biochemistry and Biomedical sciences at McMaster University. Dr. Wright co-founded GeneSense Technologies Inc. in 1996, and served as Lorus' President, Chief Scientific Officer and a member of the Board of Directors in October 1999 on a merger with GeneSense. In September 2006, he stepped down as the President and Chief Executive Officer of Lorus.

Aiping Young

 Dr. Aiping H. Young, M.D., Ph.D., is President, Chief Executive Officer, Director of Lorus Therapeutics Inc. She was a cofounder with Dr. Wright of GeneSense Technologies Inc. Dr. Young previously held the position of Chief Operating Officer, Senior Vice President, Research and Development and Chief Technology Officer at Lorus.

Elizabeth Williams

 Ms. Elizabeth Williams is Acting Chief Financial Officer, Director - Finance of Lorus Therapeutics Inc. Prior to joining Lorus in July 2004, Ms. Williams was an Audit Manager with Ernst & Young LLP. Ms. Williams is a chartered accountant and has received a bachelor’s degree in business administration.

Yoon Lee

 Dr. Yoon Lee is Vice President - Research of Lorus Therapeutics Inc. Dr. Lee has been with Lorus for ten years, most recently serving as the Director of Research. He joined Lorus in 1999 through the merger with GeneSense Technologies Inc., where he was a Research Scientist integrally involved in the development of GeneSense oligonucleotide therapeutics program.

Herbert Abramson

 Mr. Herbert Abramson is Independent Director of Lorus Therapeutics Inc. Mr. Abramson has been in the investment industry for 29 years managing portfolios for high net worth individuals. He is a co-founder, Chairman and Portfolio Manager of Trapeze Capital Corp., an investment dealer and portfolio management company and is also Chairman and Portfolio Manager of Trapeze Asset Management Inc., an affiliated investment counseling company. Mr. Abramson is a member of the Law Society of Upper Canada and practiced corporate/securities law for 12 years before going into the investment business. He is also currently a director of St Andrew Goldfields Ltd.

Denis Burger

 Dr. Denis R. Burger, Ph.D., is Independent Director of Lorus Therapeutics Inc. Dr. Burger is currently the executive Chairman of BioCurex, Inc. Dr. Burger was the past Chairman, Chief Executive Officer and a director of AVI Biopharma Inc, an Oregon based biotechnology company from 1992 to March 2007. Dr. Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in Portland, Oregon. Dr. Burger received his MSc and PhD in Microbiology and Immunology from the University of Arizona. Dr. Burger is also currently on the Board of Trinity Biotech plc. and BioCurex, Inc.

Mark Vincent

 Dr. Mark D. Vincent is Independent Director of Lorus Therapeutics Inc. Dr. Vincent is a Professor of Oncology at the University of Western Ontario and a staff medical oncologist at the London Regional Cancer Program. Dr. Vincent is also the co-founder and Chief Executive Officer of Sarissa, Inc. since 2000.

Warren Whitehead

 Mr. Warren Whitehead is Independent Director of Lorus Therapeutics Inc. Mr. Whitehead is a Certified Management Accountant who has held senior financial management positions in several biotechnology and pharmaceutical companies. Most recently he served as Chief Financial Officer of ARIUS Research Inc., providing financial guidance and leadership during the acquisition of ARIUS by Roche in 2008. Prior to that Mr. Whitehead was CFO at Labopharm Inc., where he completed a series of public equity financings and a NASDAQ IPO. He is currently a member of the board of directors of PlantForm Corporation, a life sciences company that develops biosimilar antibody drugs for treatment of cancer and other critical illnesses.

Christine Stewart

Basic Compensation

Name Fiscal Year Total

Jim Wright

 824,514

Aiping Young

 691,034

Elizabeth Williams

 96,161

Yoon Lee

 166,054

Herbert Abramson

 --

Denis Burger

 --

Mark Vincent

 --

Warren Whitehead

 --

Christine Stewart

 --
As Of 30 May 2012

Options Compensation

Name Options Value

Jim Wright

 2,472,500 0

Aiping Young

 11,726,134 0

Elizabeth Williams

 1,550,362 0

Yoon Lee

 1,562,576 0

Herbert Abramson

 0 0

Denis Burger

 0 0

Mark Vincent

 0 0

Warren Whitehead

 0 0

Christine Stewart

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks